UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 161

of 'Prognostic and predictive factors in early, nonmetastatic breast cancer'

161
TI
High levels of TIMP-2 correlate with adverse prognosis in breast cancer.
AU
Remacle A, McCarthy K, Noël A, Maguire T, McDermott E, O'Higgins N, Foidart JM, Duffy MJ
SO
Int J Cancer. 2000;89(2):118.
 
TIMP-2 is an endogenous inhibitor of MMPs. Most data from model systems suggest that high levels of this inhibitor prevent metastasis. In human breast cancers, however, we show that high levels of TIMP-2 correlate with both shortened disease-free interval and overall survival. In primary breast cancers, TIMP-2 levels showed no significant relationship with either tumor size or axillary node status but correlated inversely with estrogen receptor levels. TIMP-2 levels also correlated significantly with those for TIMP-1. We conclude that high levels of endogenous TIMP-2, like other protease inhibitors such as PAI-1 and TIMP-1, correlate with progression of human breast cancer.
AD
Laboratory of Tumor and Developmental Biology CHU, University of Liège, Sart-Tilman, Liège, Belgium.
PMID